Victor A. Gault

6.8k total citations
150 papers, 5.6k citations indexed

About

Victor A. Gault is a scholar working on Endocrinology, Diabetes and Metabolism, Cellular and Molecular Neuroscience and Surgery. According to data from OpenAlex, Victor A. Gault has authored 150 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Endocrinology, Diabetes and Metabolism, 82 papers in Cellular and Molecular Neuroscience and 59 papers in Surgery. Recurrent topics in Victor A. Gault's work include Diabetes Treatment and Management (108 papers), Neuropeptides and Animal Physiology (78 papers) and Pancreatic function and diabetes (59 papers). Victor A. Gault is often cited by papers focused on Diabetes Treatment and Management (108 papers), Neuropeptides and Animal Physiology (78 papers) and Pancreatic function and diabetes (59 papers). Victor A. Gault collaborates with scholars based in United Kingdom, Ireland and Germany. Victor A. Gault's co-authors include Peter R. Flatt, Nigel Irwin, Christian Hölscher, Finbarr O’Harte, Patrick Harriott, Paula L. McClean, Barry D. Kerr, David W. Porter, Brian D. Green and Clifford J. Bailey and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Diabetes.

In The Last Decade

Victor A. Gault

146 papers receiving 5.6k citations

Peers

Victor A. Gault
Nils Wierup Sweden
Diego Pérez–Tilve United States
Brian Finan United States
Thierry Alquier Canada
Brendan Leighton United Kingdom
Matthew J. Sanders United States
Jonathan D. Roth United States
Changiz Taghibiglou Canada
Kendra K. Bence United States
J. C. Henquin Belgium
Nils Wierup Sweden
Victor A. Gault
Citations per year, relative to Victor A. Gault Victor A. Gault (= 1×) peers Nils Wierup

Countries citing papers authored by Victor A. Gault

Since Specialization
Citations

This map shows the geographic impact of Victor A. Gault's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victor A. Gault with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victor A. Gault more than expected).

Fields of papers citing papers by Victor A. Gault

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victor A. Gault. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victor A. Gault. The network helps show where Victor A. Gault may publish in the future.

Co-authorship network of co-authors of Victor A. Gault

This figure shows the co-authorship network connecting the top 25 collaborators of Victor A. Gault. A scholar is included among the top collaborators of Victor A. Gault based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victor A. Gault. Victor A. Gault is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lafferty, Ryan A., Peter R. Flatt, Victor A. Gault, & Nigel Irwin. (2024). Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?. Journal of Endocrinology. 262(2). 3 indexed citations
2.
Tanday, Neil, et al.. (2023). A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control. Biochemical Pharmacology. 212. 115544–115544. 4 indexed citations
3.
Gault, Victor A., et al.. (2023). Peptides originally derived from Chilobrachys jingzhao tarantula venom possess beneficial effects on pancreatic beta cell health and function. European Journal of Pharmacology. 954. 175855–175855. 3 indexed citations
4.
Tanday, Neil, et al.. (2023). Sustained metabolic benefits of ΔTRTX‐Ac1 , a tarantula venom‐derived peptide, when administered together with exenatide in high‐fat fed mice. Diabetes Obesity and Metabolism. 26(1). 329–338. 2 indexed citations
5.
Gault, Victor A., et al.. (2021). A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice. Bioscience Reports. 41(8). 1 indexed citations
6.
Tanday, Neil, R. Charlotte Moffett, Victor A. Gault, Peter R. Flatt, & Nigel Irwin. (2020). Enzymatically stable analogue of the gut‐derived peptide xenin on beta‐cell transdifferentiation in high fat fed and insulin‐deficient Ins1Cre/+;Rosa26‐eYFP mice. Diabetes/Metabolism Research and Reviews. 37(3). e3384–e3384. 9 indexed citations
7.
8.
Gault, Victor A., et al.. (2020). The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin. Biochemical Pharmacology. 183. 114355–114355. 8 indexed citations
9.
Hasib, Annie, Dawood Khan, Stephen L. Craig, et al.. (2019). Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice. European Journal of Pharmacology. 865. 172733–172733. 1 indexed citations
10.
Moffett, R. Charlotte, Victor A. Gault, Neil Tanday, et al.. (2019). Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic GluCreERT2;ROSA26-eYFP mice. Peptides. 125. 170205–170205. 26 indexed citations
11.
Irwin, Nigel, Victor A. Gault, Finbarr O’Harte, & Peter R. Flatt. (2019). Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes. Peptides. 125. 170203–170203. 20 indexed citations
12.
Craig, Stephen L., Victor A. Gault, Stephen McClean, Gerd Hamscher, & Nigel Irwin. (2019). Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism. Molecular and Cellular Endocrinology. 496. 110523–110523. 11 indexed citations
13.
Gault, Victor A., et al.. (2018). Emerging therapeutic potential for xenin and related peptides in obesity and diabetes. Diabetes/Metabolism Research and Reviews. 34(6). e3006–e3006. 24 indexed citations
14.
Hasib, Annie, et al.. (2018). Exendin‐4(Lys27PAL)/gastrin/xenin‐8‐Gln: A novel acylated GLP‐1/gastrin/xenin hybrid peptide that improves metabolic status in obese‐diabetic (ob/ob) mice. Diabetes/Metabolism Research and Reviews. 35(3). e3106–e3106. 13 indexed citations
15.
Gault, Victor A., Christian Hölscher, Peter R. Flatt, et al.. (2013). Cell signalling and diabetes. Diabetic Medicine. 30(s1). 4–5. 1 indexed citations
16.
McClean, Paula L., V. Parthasarathy, Victor A. Gault, & Christian Hölscher. (2011). LIRAGLUTIDE, A NOVEL GLP-1 ANALOGUE, PREVENTS THE IMPAIRMENT OF LEARNING AND LTP AND PLAQUE FORMATION IN AN APP/PS-1 MOUSE MODEL OF ALZHEIMER'S DISEASE. Irish Journal of Medical Science (1971 -). 180(2). 1 indexed citations
17.
Hölscher, Christian, et al.. (2009). Novel GLP-1 analogues cross the blood brain barrier and enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Diabetologia. 52. 6 indexed citations
18.
Green, BD, Victor A. Gault, MH Mooney, et al.. (2004). Molecular, cellular and biological characteristics of DPP IV-resistant acetylated analogues of GLP-1.. Diabetic Medicine. 21. 26–26. 1 indexed citations
19.
Flatt, Peter R., Victor A. Gault, Patrick Harriott, & Finbarr O’Harte. (2001). Antagonist actions of novel (Pro(3))GIP analogue and GIP(3-42) on cyclic AMP production and insulin secretion. Diabetologia. 44. 1 indexed citations
20.
O’Harte, Finbarr, et al.. (2001). DPP IV resistant N-terminally modified GIP analogues with enhanced insulinotropic activity. Diabetologia. 44. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nils Wierup Breakdown of academic impact, for papers by Diego Pérez–Tilve Breakdown of academic impact, for papers by Brian Finan Breakdown of academic impact, for papers by Thierry Alquier Breakdown of academic impact, for papers by Brendan Leighton Breakdown of academic impact, for papers by Matthew J. Sanders Breakdown of academic impact, for papers by Jonathan D. Roth Breakdown of academic impact, for papers by Changiz Taghibiglou Breakdown of academic impact, for papers by Kendra K. Bence Breakdown of academic impact, for papers by J. C. Henquin
Rankless by CCL
2026